Piramal looks for 20% RoI from investment in Vodafone India but not mHealth tie-up yet
This article was originally published in Scrip
Executive Summary
Piramal Healthcare has acquired an additional 5.5% in Vodafone India from ETHL Communications Holdings (Essar) for about $600 million, as part of ongoing efforts to park funds in high-growth areas that offer better returns for the short and medium term. According to the pharma company, the move is a strictly financial venture from which it is hoping for up to a 20% return on investment, rather than a strategic move towards the application of mobile communications and network technologies for healthcare, or mHealth.